EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of One‐Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy

Jan Astermark iD, Wolfgang Miesbach iD, Michiel Coppens, Sander Gielen, Jaap Twisk, Ricardo Dolmetsch, Stephanie Verweij, Paul E Monahan, Bruce M Ewenstein, Silpa Nuthalapati, Nick Galante, Guy Young iD und 1 weitere

Haemophilia · 2025

DOI: 10.1111/hae.70053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Jan Astermark und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institution of Translational Medicine, Lund University and Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö…. Hauptthemen laut MEDLINE: Dependovirus, Factor IX, Genetic Therapy, Hemophilia B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Accurate and reproducible measures of factor activity are required to guide clinical decision‐making following gene therapy for haemophilia B (HB). Highly significant discrepancies have been observed in measurements of various factor IX (FIX) concentrates that carry molecular modifications to extend their half‐life, arguing for the need for careful analysis of new HB treatment modalities with respect to FIX assay performance.

Aim

To further characterise variability in FIX activity measured using different one‐stage assays (OSAs) and chromogenic assays (CAs) in patients with HB receiving gene therapy utilising the FIX Padua variant and to assess whether assay differences were due to the FIX‐Padua variant.

Methods

FIX activity was assessed centrally (OSA and CA) and locally (OSA only) using plasma samples collected from a phase 2b and phase 3 study of etranacogene dezaparvovec and in an in vitro study of wild‐type (wt) recombinant human FIX (rhFIX) and rhFIX‐Padua.

Results

Lower CA than OSA FIX activity for plasma samples from the phase 3 trial was observed (CA:OSA ratio: 0.408 [±0.049]–0.547 [±0.062]). Local OSA:central OSA FIX activity ratios were 0.789 (±0.314)–1.021 (±0.159). Local OSA:central OSA FIX activity ratios across methods and/or reagents were 0.81 (±0.02)–1.28 (±0.04) for rhFIX‐wt‐spiked samples and 0.67 (±0.02)–1.13 (±0.09) for rhFIX‐Padua‐spiked samples.

Conclusion

FIX activity differences between central and local OSAs were modest; similar differences were observed in vitro with rhFIX‐wt versus rhFIX‐Padua. Commonly available OSAs can be used to monitor patients post‐etranacogene dezaparvovec administration; we recommend using the same assay platform throughout the post‐treatment period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusFactor IXGenetic TherapyHemophilia BGene Therapy AgentsHumansRecombinant Proteins

Stichwörter der Autor:innen

chromogenic assayfactor IXgene therapyhaemophilia Bone‐stage assay

Substanzen

Factor IXRecombinant Proteinsetranacogene dezaparvovec

Autor:innen und Institutionen

  • Institution of Translational Medicine, Lund University and Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
  • Medical Clinic 2, Frankfurt University Hospital, Frankfurt, Germany.
  • Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands.
  • uniQure biopharma B.V., Amsterdam, The Netherlands.
  • CSL Behring, King of Prussia, Pennsylvania, USA.

ORCID-Profile: Jan Astermark, Wolfgang Miesbach, Guy Young

Förderung

  • CSL Behring

Zitieren

APA

Astermark, J., Miesbach, W., Coppens, M., Gielen, S., Twisk, J., Dolmetsch, R., Verweij, S., Monahan, P. E., Ewenstein, B. M., Nuthalapati, S., Galante, N., Young, G., & HOPE‐B study investigators (2025). Evaluation of One‐Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. Haemophilia. https://doi.org/10.1111/hae.70053

Vancouver

Astermark J, Miesbach W, Coppens M, Gielen S, Twisk J, Dolmetsch R, et al. Evaluation of One‐Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. Haemophilia. 2025. doi:10.1111/hae.70053

BibTeX
@article{Astermark2025,
  author = {Astermark, Jan and Miesbach, Wolfgang and Coppens, Michiel and Gielen, Sander and Twisk, Jaap and Dolmetsch, Ricardo and Verweij, Stephanie and Monahan, Paul E and Ewenstein, Bruce M and Nuthalapati, Silpa and Galante, Nick and Young, Guy and HOPE‐B study investigators, HOPE‐B study investigators},
  title = {Evaluation of One‐Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70053}
}
Kostenlos starten →